Full-Dose Heparin Benefit in Certain COVID-19 Patients Confirmed
A therapeutic dose of heparin was associated with increased probability of survival for non-critically ill COVID-19 patients versus usual-care thromboprophylaxis, but not for the most severe patient population, peer-reviewed results from the REMAP-CAP, ACTIV-4a, and ATTACC multi-platform trial showed. In the non-critically ill cohort, therapeutic dose anticoagulation with heparin was superior to usual care prophylaxis, […]
Fuzzy OS Benefits in Drug Labels; Zantac Suit Dismissed; Cancer Deaths Drop For Now
The overall survival benefits associated with use of many newly approved cancer drugs are often not clearly communicated in drug labels. (JAMA Internal Medicine) A reduced-dose CT scan of 0.3 mSv can safely be used to detect lung nodules in children with cancer without sacrificing diagnostic accuracy. (American Journal of Roentgenology) A federal judge has […]
PD-1 Inhibitor Boosts Survival in Treated Esophageal Cancer
Overall survival (OS) in previously treated esophageal cancer improved significantly with the anti-PD-1 drug tislelizumab compared to chemotherapy, a phase III, randomized trial showed. Patients randomized to tislelizumab had a median OS of 8.6 months as compared with 6.3 months for patients who received chemotherapy alone. A prespecified subgroup analysis of patients from Europe and […]